FULC - Company ID 0001680581
The table below shows Fulcrum Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$18.75M | -$15.26M | -$25.28M | -$24.12M | -$22.11M | -$16.23M |
| Capital expenditure | $8.00K | $0.00 | $28.00K | $171.00K | $246.00K | $262.00K |
| Investing cash flow | -$128.21M | -$777.00K | $38.13M | -$93.94M | $19.66M | $12.41M |
| Dividends paid | - | - | - |
Fulcrum Therapeutics, Inc. reported operating cash flow of -$60.06M for fiscal year 2025. That is down 2608.1% from -$2.22M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$22.56M (FY 2018) to -$60.06M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$312.00K | $0.00 | $1.65M | $117.69M | $348.00K | $47.50M |